Last 48 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.23 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.85 | 4.01 | 5.01 | 51.18 | 34.96 | 31.88 | 24.54 | 13.98 | 32.12 | 24.31 | 81.40 | 118.55 | 57.35 | 114.80 | 74.55 | 117.08 | 3900.06 | 73.28 | — | 71.35 | — |
| — | -87.4% | -79.6% | +266.1% | +8.9% | +31.1% | -69.8% | -88.2% | -44.0% | -78.8% | +9.2% | +1.3% | -98.5% | +56.7% | — | +64.1% | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | 49.44 | — | — | 5.77 | 18.25 | 3.64 | 2.25 | 2.16 | 1.95 | 1.25 | 0.95 | 1.23 | 1.66 | 1.18 |
| — | — | — | — | — | — | — | +170.9% | — | — | +166.8% | +835.3% | +191.3% | +137.0% | +75.9% | +17.3% | +6.1% | -45.3% | -40.1% | -19.8% | -73.3% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 44.6% | 55.3% | 44.6% | 33.5% | -21.7% | -4.7% | 52.0% | 31.9% | 60.0% | 61.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -4750.0% | 100.0% | — | -7.3% | — |
| — | +1265.8% | -14.3% | +5.3% | -136.2% | -107.7% | -48.0% | -68.1% | -40.0% | -38.7% | 0.0% | 0.0% | +102.1% | 0.0% | — | +1476.5% | — | — | — | — | — | |
| Operating Margin | -2454.5% | -2051.3% | -2454.5% | -3922.2% | -3285.9% | -2009.5% | -1663.6% | -1264.6% | -2679.5% | -1594.5% | -6285.4% | -7794.4% | -4964.8% | -9957.4% | -5895.5% | -8160.9% | -333950.0% | -7957.5% | — | -4476.5% | — |
| — | -2.1% | -47.5% | -210.1% | -22.6% | -26.0% | +73.5% | +83.8% | +46.0% | +84.0% | -6.6% | +4.5% | +98.5% | -25.1% | — | -82.3% | — | — | — | — | — | |
| Net Margin | -2344.6% | -1368.9% | -2496.9% | -3695.8% | -3304.5% | -1851.3% | -1909.0% | -1439.6% | -1597.8% | -1804.3% | -5967.7% | -7454.9% | -4671.4% | -9187.0% | -5818.9% | -8763.2% | -405850.0% | -7035.6% | — | -4215.8% | — |
| — | +26.1% | -30.8% | -156.7% | -106.8% | -2.6% | +68.0% | +80.7% | +65.8% | +80.4% | -2.6% | +14.9% | +98.8% | -30.6% | — | -107.9% | — | — | — | — | — |
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | -1272.7% | — | -219.8% | -157.8% | -125.1% | -55.6% | -37.7% | -35.7% | -33.3% | -31.3% | -20.7% | -24.9% | -24.7% | -24.7% |
| — | — | — | — | — | — | — | -917.3% | — | -483.5% | -342.0% | -276.1% | -77.5% | -81.8% | -43.4% | -34.8% | -27.0% | +3.9% | -7.1% | +5.4% | +11.5% | |
| ROA | -75.0% | -41.7% | -99.6% | -21.8% | -20.4% | -16.2% | -20.0% | -18.0% | -8.9% | -15.7% | -15.1% | -13.6% | -11.4% | -10.4% | -12.1% | -13.1% | -13.6% | -9.6% | -12.2% | -12.3% | -13.3% |
| — | -158.0% | -398.8% | -21.0% | -128.4% | -3.0% | -32.3% | -32.6% | +21.7% | -50.8% | -25.1% | -3.5% | +16.0% | -8.7% | +1.4% | -6.7% | -2.2% | +25.7% | +27.5% | +43.3% | +41.2% | |
| ROIC | -90.7% | -82.7% | -120.9% | -22.5% | -17.2% | -16.6% | -19.7% | -19.1% | -16.0% | -14.0% | -17.0% | -14.7% | -11.7% | -10.8% | -11.3% | -11.5% | -11.0% | -10.8% | -13.7% | -15.7% | -14.6% |
| — | -396.9% | -514.4% | -17.6% | -7.6% | -18.5% | -15.4% | -30.2% | -36.6% | -30.0% | -50.7% | -28.2% | -7.1% | +0.1% | +17.3% | +27.2% | +25.0% | +31.8% | +33.3% | +32.5% | +41.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | 64.57 | — | — | 5.47 | 16.31 | 4.60 | 2.65 | 1.95 | 1.44 | 1.18 | 1.03 | 0.89 | 0.77 | 0.79 |
| — | — | — | — | — | — | — | +296.0% | — | — | +179.8% | +1034.9% | +289.3% | +157.9% | +118.4% | +86.9% | +49.8% | +109.9% | +108.0% | +5165.0% | +2415.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.27 | 0.27 | 0.27 | 0.33 | 0.43 | 0.53 | 0.68 | 4.81 | 5.04 | 5.90 | 6.98 | 6.05 | 7.12 | 8.16 | 7.37 | 8.68 | 9.49 | 9.91 | 8.46 | 8.22 | 6.27 |
| — | -48.3% | -61.0% | -93.2% | -91.5% | -91.1% | -90.2% | -20.4% | -29.2% | -27.7% | -5.2% | -30.4% | -25.0% | -17.7% | -12.9% | +5.6% | +51.4% | +63.5% | +44.6% | +63.6% | +38.5% | |
| Quick Ratio | 0.27 | 0.27 | 0.27 | 0.33 | 0.43 | 0.53 | 0.68 | 4.81 | 5.04 | 5.90 | 6.98 | 6.05 | 7.12 | 8.16 | 7.37 | 8.68 | 9.49 | 9.91 | 8.46 | 8.22 | 6.27 |
| — | -48.3% | -61.0% | -93.2% | -91.5% | -91.1% | -90.2% | -20.4% | -29.2% | -27.7% | -5.2% | -30.4% | -25.0% | -17.7% | -12.9% | +5.6% | +51.4% | +63.5% | +44.6% | +63.6% | +38.5% | |
| Interest Coverage | -26.25 | -67.05 | -26.25 | -27.04 | -28.78 | -25.81 | -32.36 | -28.88 | -13.74 | -26.82 | -25.89 | -23.72 | -22.12 | -22.82 | -29.03 | -34.75 | -37.93 | -31.31 | -42.05 | -80.97 | -35.35 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying PLUR stock.
Pluri Inc.'s current P/E is -0.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Pluri Inc.'s current operating margin is -2454.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Pluri Inc.'s business trajectory between earnings reports.